Prostate Cancer
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care.
February 15, 2024
Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.
February 15, 2024
Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.
February 15, 2024
MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.
February 15, 2024
The yin and yang of chromosomal instability in prostate cancer.
February 14, 2024
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer.
February 14, 2024
Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations.
February 14, 2024
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
February 14, 2024
Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition.
February 13, 2024
Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.
February 13, 2024
The impact of inherited genetic variation on DNA methylation in prostate cancer and benign tissues of African American and European American men.
February 13, 2024
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
February 13, 2024
Urinary fatty acid biomarkers for prostate cancer detection.
February 13, 2024